APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences:

  • Evercore ISI HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 9:10 a.m. ET
  • Citi Global Healthcare Conference: Fireside chat on Thursday, December 5, 2024, at 1:00 p.m. ET

The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcasts will be available for approximately 90 days following the event.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit  or follow us on  and .

Investor Contact: 

Meredith Kaya 

617.599.8178



EN
27/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

 PRESS RELEASE

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences: Evercore ISI HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 9:10 a.m. ETCiti Global Healthcare Conference: Fireside chat on Thursday, December 5, 2024, at 1:00 p.m. ET The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s ....

 PRESS RELEASE

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies Londo...

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Ph...

 PRESS RELEASE

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0 million Increase in demand offset by higher gross-to-net adjustments in the quarter Following FDA feedback, on track to file an sNDA seeking approval of pegcetacoplan for C3G / primary IC-MPGN in early 2025 based on positive 6-month Phase 3 VALIANT results Cash and cash equivalents of $396.9 million as of Sept...

Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico

ResearchPool Subscriptions

Get the most out of your insights

Get in touch